ALK-Positive Criteria for Determining Crizotinib Use May Fall Short
November 4th 2013The criteria that are presently used to determine whether patients with non-small cell lung cancer may be suitable for treatment with the ALK inhibitor crizotinib may overlook some patients who may benefit from the drug.
Read More
Adjunctive Ketamine Does Not Relieve Cancer Pain
December 5th 2012Subcutaneous ketamine administered in conjunction with opioids and conventional adjuvant therapy does not lessen chronic uncontrolled cancer pain, according to the results of a phase III study. The regimen also produces a significant spike in toxicity.
Read More
Addition of Motesanib to Chemotherapy Offers No Benefit for Patients With Non-Small Cell Lung Cancer
November 27th 2012Motesanib combined with carboplatin/paclitaxel does not significantly improve OS versus carboplatin/ paclitaxel alone in patients with advanced nonsquamous non–small cell lung cancer, according to the results of the phase III MONET1 study.
Read More
Lapatinib Plus Trastuzumab Bests Lapatinib Monotherapy in HER2-Positive Metastatic Breast Cancer
November 7th 2012Investigators have documented a significant 4.5-month median overall survival advantage with lapatinib combined with trastuzumab in women with heavily pretreated HER2-positive metastatic breast cancer.
Read More
No Survival Benefit Found When Adding Bevacizumab to Gemcitabine/Cisplatin in Malignant Mesothelioma
October 31st 2012The addition of bevacizumab to gemcitabine/cisplatin does not significantly improve progression-free survival or overall survival in patients with previously untreated, unresectable malignant mesothelioma.
Read More
Extending Adjuvant Chemotherapy Offers No Additional Benefit in Low-Risk Primary Breast Cancer
October 29th 2012Six cycles of doxorubicin and cyclophosphamide or single-agent paclitaxel do not lead to a superior outcome versus four cycles as adjuvant chemotherapy in women with resected primary breast cancer.
Read More
Subcutaneous Trastuzumab May Offer Benefits Over Standard IV Infusion in Patients With Breast Cancer
September 26th 2012A new formulation of trastuzumab that is administered subcutaneously appears to be as effective as the approved bodyweight-based intravenous regimen in women with HER2-positive breast cancer.
Read More
Biomarker Predicts Survival Benefit in Advanced Kidney Cancer Treated With TORC1 Inhibitor
September 26th 2012Pretreatment serum lactate dehydrogenase is a prognostic factor in poor-risk patients with renal cell carcinoma and also a predictive factor for a survival benefit from treatment with temsirolimus.
Read More